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Many treatment options exist for prostate can-
cer and newer targeted treatments are being 
developed based on current research [3, 4]. 
However, prostate cancer mechanisms of initia-
tion and progression are not completely under-
stood. 
 
The idea that inflammation may be a precursor 
to cancer has been proposed for many types of 
cancer.  Epidemiological evidence supports this 
theory in the respiratory, genitourinary, repro-
ductive and gastrointestinal systems [5, 6]. 
Chronic inflammation occurs due to macro-
phages, lymphocytes and plasma cells infiltrat-
ing damaged tissue [5]. All of these leukocytes 
can release potentially harmful products such 
as reactive oxygen species (ROS), cytokines, 
and other mediators [6], which may contribute 
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Abstract: Chronic inflammation is proposed to prime the development of prostate cancer. However, the mechanisms 
of prostate cancer initiation and development are not completely understood. The αvβ6 integrin has been shown to 
play a role in epithelial development, wound healing and some epithelial cancers [1, 2]. Here, we investigate the ex-
pression of αvβ6 in mouse models of prostatic inflammation and prostate cancer to establish a possible relationship 
between inflammation of the prostate, αvβ6 expression and the progression of prostate cancer. Using immunohisto-
chemical techniques, we show expression of αvβ6 in two in vivo mouse models; the Ptenpc-/- model containing a pros-
tate-specific Pten tumor suppressor deletion that causes cancer, and the prostate ovalbumin-expressing transgenic 
(POET) inflammation mouse model. We show that the αvβ6 integrin is induced in prostate cancer and inflammation in 
vivo in these two mouse models. αvβ6 is expressed in all the mice with cancer in the Ptenpc-/- model but not in age-
matched wild-type mice. In the POET inflammation model, αvβ6 is expressed in mice injected with activated T-cells, 
but in none of the control mice. In the POET model, we also used real time PCR to assess the expression of Trans-
forming Growth Factor Beta 1 (TGFβ1), a factor in inflammation that is activated by αvβ6. In conclusion, through in 
vivo evidence, we conclude that αvβ6  integrin may be a crucial link between prostatic inflammation and prostatic ade-
nocarcinoma. 
 
Keywords: Prostate cancer, PIN lesion, chronic inflammation, TGFβ1, αvβ6 integrin, Akt 
αVβ6 integrin, prostatic inflammation and adenocarcinoma 
 
 
166                                                                                                              Am J Transl Res 2012;4(2):165-174 
to the onset of cancer [5]. 
 
Prostatic inflammation has been linked to pros-
tate cancer through epidemiological, histopa-
thological and molecular pathological studies 
[7]. The morphologic entity known as prostate 
inflammatory atrophy (PIA) may be a precursor 
lesion to the onset of prostate cancer. In some 
cases, PIA can progress to prostatic intraepithe-
lial neoplasia (PIN) and invasive cancer; how-
ever, not all cases of prostate cancer are pre-
ceded by PIA or PIN [8]. 
 
Integrins are transmembrane heterodimers con-
sisting of α and β subunits [9-11]. They bind 
extracellular matrix (ECM) proteins and may, in 
some instances, mediate cell-cell contacts [12]. 
Integrins activate many signaling pathways, in-
cluding the PI-3kinase/Akt pathway [13] and 
CDKs [14, 15], which affect proliferation and 
the cell cycle. Different integrins have been 
shown to be both over- and under- expressed in 
different cancers [16] and the role of integrins 
in the progression of prostate cancer has been 
recently reviewed [17]. Among others, the αvβ6 
integrin is a potential target that may link in-
flammation and cancer. This integrin has been 
sequenced in humans, guinea pigs [18] and 
mice [19] and has been shown to pair with only 
one alpha subunit (αv) and to bind fibronectin 
tenascin, vitronectin and osteopontin [20, 21]. 
Additionally,  β6 integrin subunit is only ex-
pressed in epithelial cells and is not detectable 
in most resting, fully differentiated epithelia, 
including those in the lungs and skin [22]. How-
ever, this integrin is shown to be expressed in 
wound healing and some cancers [1, 2, 23, 24].  
 
Here, we have evaluated αvβ6 integrin expres-
sion in two in vivo murine models of prostate 
diseases. Both models utilize the Cre-Lox sys-
tem with the prostate-specific promoter ARR2PB 
originally developed by X. Wu and co-workers 
[25]. This system has been used to conditionally 
delete the Pten tumor suppressor in the pros-
tate of mice [26]. This tumor suppressor is often 
inactivated in human prostate cancer [27, 28]. 
These mice develop PIN at an early age and 
then, later, invasive adenocarcinoma. The other 
model, the prostate ovalbumin-expressing/
transgenic (POET) model [29], used this system 
to express a gene of a membrane-bound, oval-
bumin-transferring, receptor fusion protein in 
the prostate. This model is used to mimic in-
flammation of the prostate and these mice have 
not been reported to develop cancer of the pros-
tate. 
 
Materials and methods 
 
Cells, reagents and antibodies 
 
PC3 cells were cultured in RPMI medium con-
taining 5% fetal bovine serum (FBS) (Atlanta 
Biologicals, Norcross, GA). TGFβ1 was from R&D 
System Inc. The antibodies used were: rabbit 
antibodies against ERK1/2 from Santa Cruz 
Biotechnology (Santa Cruz, CA), p-Akt (ser473) 
and Akt from Cell Signaling Technology (Beverly, 
MA) and monoclonal mouse antibody 2A1 to β6 
for immunoblotting [30, 31]. β6 siRNA duplexes 
(IDT, Inc.) were: D2 (sense) 5’-ACC ACG GGA 
ACG GCU CUU UCC AGT G-3’ and (antisense) 5’-
CAC UGG AAA GAG CCG UUC CCG UGG UGA-3’. A 
non-silencing siRNA duplex, 5’-CUU CCUCUC 
UUU CUC UCC CUU GUG A-3’ and 5’-UCA CAA 
GGG AGA GAA AGA GAG GAA GGA-3’, was used 
as a control. SiRNA duplexes were transfected 
using oligofectamine at a final concentration of 
20 nM. Twenty-four hours after two round-
transfections, cells were harvested to test ex-




Cell lysates were prepared, separated by SDS-
PAGE gel and analyzed by IB as previously de-
scribed [20]. Frozen tumor tissues collected 
from a bone injection site were homogenized as 
previously described [32]. 
 
Generation of mouse models 
 
All Ptenpc-/- mice were generated in Dr. Pradip 
Roy-Burman laboratory. All POET-3 mice were 
generated in Dr. Timothy L. Ratliff laboratory. All 
β6-null murine tissues were provided by Drs. 
Shelia Violette and Dean Sheppard. We bred 
Ptenpc-/- mice as described by S. Wang et al. 
[26]. Prostate tissue was collected at 7/8, 12, 
20, 28, and 44 weeks of age. The POET-3 in-
flammation model was developed as previously 
reported [29]. Inflammation was induced by the 
injection of 5 x 106 ovalbumin specific T-cells 
(OT-I cells) and prostate tissue was collected 
after 7 days. Animal studies were conducted in 
accordance with approved Institutional Animal 
Care and Use Committee protocols and the Na-
tional Institutes of Health Guide for the Care 
and Use of Laboratory Animals. 
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Immunohistochemistry (IHC) 
 
IHC was performed as previously described in 
Hahm et al [33], employing the monoclonal anti-
body ch2A1 directed against αvβ6 integrin while 
a class-matched monoclonal human IgG anti-
body was used as a control for immunostaining. 
All slides were reviewed by microscopy using an 
Olympus BX41TF optical microscope equipped 
with an Evolution MP 5.0 RTV digital camera 
attached to a computer. Digital images were 
captured using QCapture Pro software. Immuno-
histochemically stained slides were reviewed 
and prostate gland lobes (dorsolateral, ventral 
and anterior) were scored individually for the 
presence of invasive adenocarcinoma, as well 
as for the percentage of neoplastic cells that 
expressed αvβ6 integrin when adenocarcinoma 
was present. 
 
Real time PCR (RT-PCR) 
 
RNA used for RT-PCR was harvested from up to 
20 mg of tissue using the RNeasy Mini Kit® 
(Qiagen; Valencia, CA) and accompanying Qi-
ashredder® (Qiagen) and RNase-Free DNase Set 
(Qiagen). Yield was determined by UV spectro-
photometry. RNA was added to 50 ng of Ran-
dom Hexamer/pd(N)6 (Roche, Basel, Switzer-
land) to a volume of 10µl in RNase-free water. 
RNA and Oligo dT were heated to 65°C for 5 
minutes and immediately placed on ice. The 
RNA/random hexamer mix was added to 10µl of 
a RT reaction mix ((2× First Strand Buffer; Invi-
trogen; Carlsbad, CA), 10 mm dithiothreitol 
(DTT), 2 mm dinucleotide triphosphate (dNTP) 
mix, 40 U RNasin® (Promega Biosciences, San 
Luis Obispo, CA), and 200 U Superscript II® Re-
verse Transcriptase (Invitrogen)) and incubated 
in sequence at 25°C for 10minutes, 50°C for 
50 minutes, 85°C for 5 minutes, and stored at 
4°C. Two µl of the RT reaction were used in a 
25 µl total PCR reaction containing: 0.5 µm 
TGFβ primers (TaqMan gene expression assay 
Mm01178820_m1 from Applied Biosystems), 
200 µm dNTP mix, 1× PCR Buffer (Roche), 2.5 U 




Mann-Whitney test was used to analyze the sig-
nificance of TGFβ1 RNA expression fold 
changes in POET mice as compared with 




The αvβ6 integrin is expressed in prostatic ade-
nocarcinoma in the Ptenpc-/- mouse model 
 
In the Ptenpc-/- mouse prostate using immuno-
histochemical analysis, we detect expression of 
the αvβ6 integrin in PIN (data not shown) and 
invasive adenocarcinoma (Figure 1), whereas 
αvβ6 expression is undetectable in the normal 
prostate gland of age-matched wild-type mice 
(Figure 1). More than 90% of the animals be-
tween seven and 46 weeks of age have evi-
dence of adenocarcinoma in the prostate gland 
most notably in the dorsolateral lobe (Table 1). 
In all animals where adenocarcinoma pre-
sented, αvβ6 staining is seen within the adeno-
carcinoma in at least one lobe (Table 1). As ex-
pected, expression of αvβ6 is readily detectable 
in malignant epithelial cells, but is never de-
tected within the stroma, or in the epithelium of 
wild-type prostates (Figure 1). 
 
The αvβ6 integrin is induced during inflamma-
tion of the prostate 
 
In the POET-3 mouse model, we also show focal 
expression of αvβ6 within epithelial cells of in-
flamed glands (Figure 2). Flow cytometric analy-
sis shows strong prostate infiltration of leuko-
cytes in ventral, dorsolateral and anterior pros-
tate (data not shown). No staining occurred in 
the control group, indicating that the positive 
staining was a result of inflammation (Figure 2). 
The number of mice injected with activated T-
cells and positive staining for αvβ6 expression in 
the prostate gland over time are presented in 
Table 2. These data demonstrate a strong asso-
ciation in the POET model between activated T-
cells and αvβ6 expression that decreases over 
time. 
 
TGFβ1 mRNA expression is increased in the 
POET model 
 
The expression of TGFβ1 mRNA is increased 
during inflammation in the POET model as de-
termined by quantitative RT-PCR (Figure 3). Fig-
ure 3 shows that the TGFβ1 mRNA expression 
in prostate tissues from the POET-3 mice is 
greater than that seen in prostate tissues iso-
lated from C57BL/6 mice receiving OT-I cells. 
The increase is seen as early as 7 days post 
injection and remains elevated 14 days post-OT-
I-injection (Figure 3). The increased expression 
αVβ6 integrin, prostatic inflammation and adenocarcinoma 
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Figure 1. αvβ6 Expression in the Ptenpc-/- Mouse Model of Prostate Cancer. Ptenpc-/- mice at ages 8 to 44 weeks show 
strong expression of αvβ6 in malignant epithelial cells of invasive adenocarcinoma (A, B, C, D, E) as evaluated using 
ch2A1, a monoclonal antibody specific for αvβ6; non-immune mouse IgG were used  a control (F, G, H, I, J). αvβ6 is not 
expressed in prostate epithelial cells from Pten wild type (WT) littermate controls (K, L, M, N, O). CK14 is a basal 
marker whose expression is lost during cancer; this marker is shown to be more heavily expressed in PIN than in can-
cer. The dorsolateral lobes are shown in this Figure.  
αVβ6 integrin, prostatic inflammation and adenocarcinoma 
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 Table 1. Distribution of αvβ6 integrin in PIN and Adenocarcinoma in the Ptenpc-/- Model. The percentage of PIN and 
adenocarcinoma cells exhibiting positive staining for αvβ6 integrin  is shown by prostate lobe. The dorsal and lateral 
lobe values were combined. AdCa, adenocacinoma. AP, anterior prostate. DLP, dorso-lateral prostate. VP, ventral 
prostate. -, not available, mo, months. 
Age (mo) Tissue % AdCa Cells Stained   Age (mo) Tissue % AdCa Cells Stained 
1.7 AP -   7 AP 0 
1.7 DLP -   7 DLP 75 
1.7 VP -   7 VP 100 
2 AP -   8.5 AP 0 
2 DLP 100   8.5 DLP 100 
2 VP -   8.5 VP - 
3.1 AP -   9.4 AP - 
3.1 DLP 100   9.4 DLP 100 
3.1 VP 100   9.4 VP 0 
3.9 AP -   10 AP - 
3.9 DLP 75   10 DLP 5 
3.9 VP 0   10 VP 0 
5 AP -   11 AP 100 
5 DLP 100   11 DLP 100 
5 VP 0   11 VP 100 
5.1 AP 0   11.2 AP 60 
5.1 DLP 100   11.2 DLP 75 
5.1 VP -   11.2 VP 50 
5.8 AP 100   11.6 AP 75 
5.8 DLP 80   11.6 DLP 100 
5.8 VP 50   11.6 VP 0 
 
Figure 2. αvβ6 Expression in the POET Model of Prostate Inflammation. αvβ6 Expression in the POET Model of Prostate 
Inflammation. The expression of αvβ6 integrin is seen focally in glandular epithelium of the ventral prostate in associa-
tion with interstitial inflammation (right panel), as evaluated using ch2A1, a monoclonal antibody specific for αvβ6. No 
inflammation or αvβ6 integrin expression is seen where there are no activated T-cells (left panel). Tissues were col-
lected 14 days post-injection. VP, ventral prostate. 
αVβ6 integrin, prostatic inflammation and adenocarcinoma 
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of TGFβ1 is most prominent in the anterior pros-
tate (Figure 3). 
 
αvβ6 is not required for normal prostate gland 
development 
 
Hematoxylin and eosin stained sections of each 
prostate gland lobe from β6 -null mice were ex-
amined to evaluate whether constitutive expres-
sion of the β6 integrin subunit is necessary for 
prostate gland development. The results show 
that the morphology of prostate glands from 
mice that lack the β6 integrin  and wild-type ani-
mals was similar (Figure 4). Normal morphology 
is seen in all four lobes of β6 -null mice (Figure 
4), indicating that this integrin is not essential 
for proper morphological maintenance of the 
prostate. 
 
αvβ6 downregulation does not affect Akt activa-
tion in PC3 cells 
 
αvβ6 integrin expression has been shown to be 
associated with neoplastic and metastatic phe-
notypes [34]. To investigate if the β6 integrin 
has an effect on the Akt pathway, known to pro-
mote androgen-independent survival and 
growth of prostate cancer cells [35], we down-
regulated β6 in PC3 cells using β6 siRNA and 
measured activation of Akt using antibody spe-
cific to phospho-Akt. The results show that 
downregulation of β6 does not have an effect on 
activation of Akt (Figure 5A). Downregulation of 
β6 integrin  was confirmed by immunoblotting 
(Figure 5B). Our results suggest that expression 
of β6 integrin  in prostate cancer cells does not 
regulate the Akt signaling pathway, which ap-





In this study, we show that the αvβ6 integrin is 
expressed in both the Ptenpc-/- and the POET-3 
mouse models of, respectively, cancer and in-
flammation. In the Ptenpc-/- mouse model, we 
show, in PIN and invasive adenocarcinoma, 
epithelial-specific αvβ6 integrin expression which 
is instead undetectable in the normal prostate 
gland of age-matched wild-type mice. In the 
POET-3 mouse model, we show αvβ6 expression 
within epithelial cells of inflamed prostate 
glands, but not in the control group. In addition, 
we show that constitutive expression of the β6 
integrin is not necessary for prostate gland de-
velopment, since the prostate gland morphology 
of mice that lack the β6 integrin  and wild-type 
animals are comparable. This integrin, and its 
downstream signaling, may be a link between 
inflammation and cancer in the prostate. 
 
αvβ6 integrin expression during inflammation 
Figure 3. TGFβ1 mRNA levels in the Inflamed POET-3 
Prostate. Ventral, anterior, and dorso-lateral prostate 
lobes were harvested from C57BL/6 and POET-3 
mice at 4, 7 and 14 days after transfer of pre-
activated OT-I cells. Prostate tissues were homoge-
nized and RNA was isolated, reverse transcribed and 
real time PCR was performed with primers for TGFβ1. 
P<0.05, Mann-Whitney test. 
Table 2. Number of Mice Injected with Activated T-cells and αvβ6 Integrin Staining in the POET Model. The number of 
mice injected with activated T-cells and positive staining for αvβ6 are shown at 8, 14, and 21 days post-OT-I-
injection. The control group of three mice did not receive the OT-I injection and did not exhibit T-cell activation or 
positive staining for αvβ6. 
Time (days) case Activated T-cells Positive Staining for 
Post-Injection (n)     
8 9 9 8 
14 9 7 4 
21 12 7 2 
control 3 0 0 
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and adenocarcinoma in the mouse models em-
ployed for this report adds to the current evi-
dence supporting inflammation as a precursor 
to cancer in the prostate. However, due to the 
transient nature of inflammation in the POET 
model, inflammation is not sustained for a pe-
riod of time sufficient to induce adenocarci-
noma; in our system, the levels of αvβ6 staining 
decrease between 14 and 21 days post-
injection even though the number of activated T
-cells remained the same. Further research with 
an in vivo model of chronic inflammation may 
confirm these results. In the Ptenpc-/- model, PIN 
develops as a precursor to malignancy-as is 
believed to be the case in humans. In this 
model, mice containing the conditional deletion 
of Pten develop adenocarcinoma and show in-
creased expression of αvβ6 in association with 
invasive adenocarcinoma. However, PIN and 
adenocarcinoma develop at an early age-as 
young as 7 weeks-making it hard to determine if 
inflammation occurs prior to PIN and adenocar-
cinoma in this model. In humans, prostate can-
cer does not develop until later in life, allowing 
time for chronic inflammation to possibly play a 
role in the progression to cancer. 
 
At the molecular level, some similarities be-
tween inflammation and cancer of the prostate 
may exist. For example, the enzyme COX-2, 
Figure 4. Histological Evaluation of Murine Prostate from β6-null and Wild-type Mice. β6-null mice have normal pros-
tate morphology compared with prostates isolated from wild type mice. Normal morphology is seen in all lobes. AP, 
anterior prostate. DP, dorsal prostate. LP, lateral prostate. VP, ventral prostate.  
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which is involved in the breakdown of arachi-
donic acid, has been implicated in the progres-
sion of inflammation to cancer [36]. Some stud-
ies have shown this enzyme to be over-
expressed in PIN [37] and prostate cancer [37-
41]. However, a recent study suggests that over-
expression of COX-2 occurs only during inflam-
mation and not during cancer [42]. One group 
found that neither genetic nor therapeutic inhi-
bition of COX-2 affected prostate carcinogenesis 
in TRAMP mice [Wang et al, personal communi-
cation]. Some genetic mutations in this gene 
have been shown to affect prostate cancer risk 
[43] and inhibition of COX-2 has been shown to 
limit the effects of αvβ6, including preventing 
Rac-1 activation in an oral squamous cell carci-
noma cell line [44]. Both COX-2 and ROS have 
been proposed to explain the progression from 
inflammation to cancer in many models. Some 
of the genetic mutations found in prostate can-
cer also support this theory; for example, lack of 
expression of the immune response proteins 
RNASEL and MSR1 can lead to chronic inflam-
mation due to loss of, or alteration of, immune 
functions [45]. 
 
We also show transcriptional upregulation of 
TGFβ1 in the in vivo model of prostatic inflam-
mation. The interaction of TGFβ1 with αvβ6 in-
tegrin may play a key role in the molecular sig-
naling associated with inflammation and pro-
gression to cancer in the prostate gland. TGFβ1 
is known to interact with, and become activated 
by, the αvβ6 integrin. This growth factor is also 
important in inflammation as it is synthesized, 
and released, by active T-cells [46-48]. TGFβ1 
can induce apoptosis and regulate cell growth, 
as well as function as a tumor suppressor [49]. 
Other studies have also linked TGFβ1 over-
expression to poor clinical prognosis [49]. 
TGFβ1 can actually support metastasis and tu-
mor invasion [49], thus αvβ6 activation of TGFβ1 
reveals a possible role for αvβ6 in metastasis. A 
potential correlation between levels of the αvβ6 
integrin and of activated TGFβ1 in human pros-
tate cancer will need to be addressed in future 
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